	US 12,435,139 B2
	Antibody constructs for DLL3 and CD3
Tobias Raum, Munich (DE); Claudia Blümel, Munich (DE); Christoph Dahlhoff, Munich (DE); Patrick Hoffmann, Munich (DE); Peter Kufer, Munich (DE); Ralf Lutterbüse, Munich (DE); Elisabeth Nahrwold, Munich (DE); and Jochen Pendzialek, Munich (DE)
Assigned to AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed by AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed on Dec. 21, 2022, as Appl. No. 18/069,704.
Application 16/868,257 is a division of application No. 16/291,826, filed on Mar. 4, 2019, granted, now 10,683,351, issued on Jun. 16, 2020.
Application 16/291,826 is a division of application No. 15/225,107, filed on Aug. 1, 2016, granted, now 10,294,300, issued on May 21, 2019.
Application 18/069,704 is a continuation of application No. 16/868,257, filed on May 6, 2020, granted, now 11,591,396.
Claims priority of provisional application 62/290,896, filed on Feb. 3, 2016.
Claims priority of provisional application 62/199,930, filed on Jul. 31, 2015.
Prior Publication US 2023/0312717 A1, Oct. 5, 2023
Int. Cl. C07K 16/18 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/07 (2010.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01); C07K 14/475 (2006.01); C07K 14/725 (2006.01)

CPC C07K 16/2809 (2013.01) [A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 40/11 (2025.01); A61K 40/4225 (2025.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C12N 5/06 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/55 (2023.05); A61K 2239/57 (2023.05); C07K 16/22 (2013.01); C07K 16/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

12 Claims

1. A bispecific antibody construct comprising a first binding domain which binds an epitope of human Delta-like Ligand 3 (DLL3) on the surface of a target cell within the amino acid sequence of SEQ ID NO: 269 and a second binding domain which binds human CD3 on the surface of a T cell, wherein the first binding domain comprises a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of:

a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 171, CDR-H2 comprising the amino acid sequence of SEQ ID NO: 172, CDR-H3 comprising the amino acid sequence of SEQ ID NO: 173, CDR-L1 comprising the amino acid sequence of SEQ ID NO: 174, CDR-L2 comprising the amino acid sequence of SEQ ID NO: 175 and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 176;

b) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 181, CDR-H2 comprising the amino acid sequence of SEQ ID NO: 182, CDR-H3 comprising the amino acid sequence of SEQ ID NO: 183, CDR-L1 comprising the amino acid sequence of SEQ ID NO: 184, CDR-L2 comprising the amino acid sequence of SEQ ID NO: 185 and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 186;

c) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 191, CDR-H2 comprising the amino acid sequence of SEQ ID NO: 192, CDR-H3 comprising the amino acid sequence of SEQ ID NO: 193, CDR-L1 comprising the amino acid sequence of SEQ ID NO: 194, CDR-L2 comprising the amino acid sequence of SEQ ID NO: 195 and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 196; and

d) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 201, CDR-H2 comprising the amino acid sequence of SEQ ID NO: 202, CDR-H3 comprising the amino acid sequence of SEQ ID NO: 203, CDR-L1 comprising the amino acid sequence of SEQ ID NO: 204, CDR-L2 comprising the amino acid sequence of SEQ ID NO: 205 and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 206.